Of course more focus/information flow is going to happen around the lead candidate drug but I don’t agree with the comment that “they seemed to narrow focus down to just that 1 potential drug”.
It's just 9 months since the Company announced that its initial target would be retinal disease
We have previously advised that we are building our delivery platform in the context of AntiSense Oligonucleotide (ASO) drug cargoes…. Our choice of drug cargo has been complemented by a decision on our initial target tissue of interest. We are seeking to deliver these ASO cargoes into the back of the eye to address diseases occurring in the retina. (29/04/19)
And within the next few months it was made clear that the objective was to develop multiple drugs for retinal diseases.
The treatment of inherited retinal diseases is the priority setting for the clinical development of our platform. (27/06/19)
Our CPP enables the ASO to achieve its effect in the nucleus of cells….We can leverage these results to treat any retinal disease of interest
Objective - We are developing multiple drugs for the treatment of blinding eye diseases and are taking them through clinical development (24/07/19)
Just 4 months ago, it was announced that PYC was partnering with Lions Eye Institute, appointing Prof. Sue Fletcher as Chief of R & D and selecting Retinitis Pigmentosa as its lead pipeline indication. But, even then, it was made clear that multiple drugs were being developed
Previously PYC has been advancing its cell penetrating peptide technology as a platform to deliver drugs. Now it will be combining that technology with drugs to internally develop a new class of therapies to cure blinding diseases of the eye.
Sue Fletcher “We look forward to the clinical development of therapeutics for Retinitis Pigmentosa and other degenerative retinal diseases” (01/10/19)
In the Annual Report it was stressed that the lead program was merely “the tip of the iceberg” and that second and third programs in retinal disease were already underway
Not only has our delivery technology improved and matured to the quality required for human therapeutics but we have also recruited and developed the capability to design RNA therapeutics ‘in-house’. PYC’s lead program is the ‘tip of the iceberg’ in the development pipeline and PYC’s second and third drug programs benefit from great efficiencies in the design and testing of the delivery technology already completed. (18/10/19)
Finally, last month, it was announced that the pipeline was being expanded both in inherited retinal diseases and to evaluation of target tissues and indications beyond the eye.
As stated in this latest announcement
The relatively short amount of time required to design a new RNA therapeutic once the target opportunity has been identified is a major advantage of this class of drugs.
They are simply leveraging that major advantage and getting on with it. I think they’d be crazy not to.
Add to My Watchlist
What is My Watchlist?
